“Alvea’s Story, Wins, and Challenges [Unofficial]” by kyle_fish

IntroA few months ago, the other (former) Alvea executives and I made the difficult decision to wind Alvea down and return our remaining funding to investors. In this post, I’ll share an overview of Alvea's story and highlight a few of our wins and challenges from my perspective as an Alvea Co-Founder and former CTO, in hopes that our experiences might be useful to others who are working on (or considering) ambitious projects to solve the biggest problems in the world. I’m sharing everything below in a personal capacity and as a window into my current thinking—this is not the definitive or official word on Alvea and it doesn’t necessarily represent the views of any other Alvea team members. I expect my reflections to continue evolving as I further process the journey and outcomes of this project, and hope to share more along the way. Alvea's StoryFirst vaccine sprint and [...] ---Outline:(00:05) Intro(00:55) Alvea's Story(00:59) First vaccine sprint and decision to continue Alvea (December 2021 through April 2022)(02:48) Product pursuits (May 2022 through July 2022)(04:04) Second vaccine sprint (August 2022-December 2023)(05:22) Funding environment change and pivot (Dec 2022 - May 2023)(07:33) Wind down and PanLabs spin out (June-Present)(09:08) Wins(09:11) Record time to safe clinical development(10:12) General-purpose rapid drug development capacity(11:12) Team Development(12:09) Medical countermeasure knowledge(13:02) Challenges(13:22) Challenges of rapid growth(14:21) Costs of complex non-standard corporate set up(15:00) Navigating the transition from short- to long-term goals(16:12) Conclusion--- First published: November 1st, 2023 Source: https://forum.effectivealtruism.org/posts/d9bamQHBAwAjuKtNA/alvea-s-story-wins-and-challenges-unofficial --- Narrated by TYPE III AUDIO.